Treatment Magazine Reports on Vigabatrin Clinical Trial Failure and The Chilling Impact on Further Addictions Drug Development

November 10, 2012 –– A new Treatment Magazine’s article provides an in depth look at last week’s disappointing clinical trial results for the closely watched, NIDA-backed, addictions compound Vigabatrin and how this could have a chilling effect on further investments by private drug companies in research and development of drugs to combat addiction and to be used in addiction treatment.

To read the article, please visit:
http://www.treatmentmagazine.com/newswires/338-catalyst-pharma-plunges-as-key-vigabatrin-trial-disappoints.html

Contact Information

Ted Jackson

Editor and Publisher

Treatment Magazine

(1) 561-702-4235

ted@treatmentmagazine.com